Let’s dig into the relative performance of Viatris (NASDAQ:VTRS) and its peers as we unravel the now-completed Q4 generic ...

We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential. In this ...

Pfizer's robust product pipeline and consistent R&D investments position it well for future growth. See why I rate PFE stock ...

Pfizer Inc. stock hits a 12-year low due to M&A missteps and high debt. Click here to find out why I rate PFE stock a Hold.

Dow's steep stock decline has boosted its dividend yield significantly. LyondellBasell's yield isn't too far behind Dow's, ...

Pfizer (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the U.S.

Pfizer has a very low valuation and a sky-high dividend yield. But this could be a broken stock, not so much a broken company. Pfizer's product sales could churn as patents expire, but the stock ...

Pfizer recently saw the European Commission expand ... Recent earnings reports highlighted a notable improvement, with Q4 2024 revenue reaching US$17.76 billion from US$14.57 billion in Q4 2023.